NEFL and myeloid sarcoma: Further, approximately 60% of patients with high CSF NF-L levels (>386 ng/mL) converted from RR-MS to secondary progressive MS (SP-MS) within the 14-year followup period compared to 30% of patients with moderate or low levels (<386 ng/mL).